Ping Ma

Ping Ma

Auto-generated profile, based on publicly available information

Ping Ma

Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, 94143, USA; Department of Ophthalmology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
PMPing Ma
Ping Ma
YWYanyan Wu
Yanyan Wu
JOJulius Oatts
Julius Oatts
JPJutima Patlidanon
Jutima Patlidanon
YYYinxi Yu
Yinxi Yu
YHYing Han
Ying Han

9 March 2022 in Experimental Eye Research
Verified
Journal Article
Open access
MZMengya Zhao
Mengya Zhao
PMPing Ma
Ping Ma
QXQinghong Xie
Qinghong Xie
ABAnh D. Bui
Anh D. Bui
SYSean Yonamine
Sean Yonamine
YHYing Han
Ying Han
Glaucoma is a heterogeneous group of progressive optic neurodegenerative. Although most patients with primary open angle glaucoma (POAG) are stable for many years, certain subgroups of POAG patients could progress over time even with treatment. This study is to identify aqueous humor (AH) biomarkers that may be associated with disease progression in POAG patients. Gene differential expression study of prospectively collected AH from patients with stable or progressive POAG. Metagenomic deep sequencing (MDS) was performed on the aqueous fluid of 20 patients with stable POAG and 20 patients with progressive POAG. Differential gene expression analysis was performed to identify host transcriptome signatures. A total of 21 transcripts were differentially expressed between groups. Differential transcripts identified by MDS. Twenty transcripts were up-regulated and 1 transcript was down-regulated in progressive POAG patients compared to stable patients. Of those, 11 transcripts were eye-related, and 5 transcripts were related to glaucomatous phenotypes (Fibronectin type III domain containing 3B (FNDC3B), Clusterin (CLU), Proprotein convertase subtilisin/kexin type 6 (PCSK6), Cadherin EGF LAG seven-pass G-type receptor 1 (Celsr1), and Rho guanine nucleotide exchange factor 4 (ARHGEF4)). Biomarkers associated with POAG progression can be identified from aqueous fluid. Identification of the biomarkers may improve glaucoma surveillance for progressive POAG.